GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » Net Cash per Share

Tengion (Tengion) Net Cash per Share : $-3.35 (As of Sep. 2014)


View and export this data going back to 2010. Start your Free Trial

What is Tengion Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Tengion's Net Cash per Share for the quarter that ended in Sep. 2014 was $-3.35.

The historical rank and industry rank for Tengion's Net Cash per Share or its related term are showing as below:

TNGNQ's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.04
* Ranked among companies with meaningful Price-to-Net-Cash only.

Tengion Net Cash per Share Historical Data

The historical data trend for Tengion's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tengion Net Cash per Share Chart

Tengion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Net Cash per Share
Get a 7-Day Free Trial -158.67 -0.90 1.05 -6.63 -3.09

Tengion Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.38 -3.09 -2.90 -3.20 -3.35

Competitive Comparison of Tengion's Net Cash per Share

For the Biotechnology subindustry, Tengion's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tengion's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Tengion's Price-to-Net-Cash falls into.



Tengion Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Tengion's Net Cash per Share for the fiscal year that ended in Dec. 2013 is calculated as

Net Cash per Share (A: Dec. 2013 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(21.51-42.58-0)/6.822
=-3.09

Tengion's Net Cash per Share for the quarter that ended in Sep. 2014 is calculated as

Net Cash per Share (Q: Sep. 2014 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(5.728-93.003-0)/26.05
=-3.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tengion  (GREY:TNGNQ) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Tengion Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Tengion's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Tengion (Tengion) Business Description

Traded in Other Exchanges
N/A
Address
3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Executives
John L Miclot director, officer: President and CEO 5005 OLD ORCHARD LANE, GIBSONIA PA 15044
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
A Brian Davis officer: Chf. Fin. Offr, VP Fin. C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Medtronic Inc 10 percent owner 710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432
Johan Christenson 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Staffan Lindstrand 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Mark Stejbach officer: VP and Chief Commercial Offcr C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Steven Nichtberger director, officer: President and CEO C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Oak Investment Partners Xi L P 10 percent owner 901 MAIN AVENUE, SUITE 600, NORWALK CT 06851

Tengion (Tengion) Headlines

From GuruFocus

Tengion Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-20-2010